drugset / Trial / NCT05723510
PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.
Timeline
- Start
- 2023-03-06
- Primary completion
- 2023-07-17
- Completion
- 2023-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 5 mg | Oral |
| Subject | Edoxaban | Small molecule | 60 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 50 mg | Oral |
Indications
No indication recorded.